期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

中国绝经前女性乳腺癌患者辅助治疗后绝经判断标准及芳香化酶抑制剂临床应用共识 被引量：7

下载PDF
导出
摘要 我国乳腺癌的发病率呈逐渐升高的态势，其中绝经前的患者较多。早期乳腺癌的辅助治疗包括化疗、放疗以及内分泌治疗等，其中一些治疗会影响绝经前女性患者的卵巢功能，从而影响患者的月经状态；同时乳腺癌患者接受内分泌治疗的方式也与患者的月经状态密切相关。
机构地区 中国抗癌协会乳腺癌专业委员会
出处 《中国癌症杂志》 CAS CSCD 北大核心 2012年第3期238-240,共3页 China Oncology
关键词 乳腺癌患者 绝经前女性 辅助治疗 芳香化酶抑制剂 临床应用 内分泌治疗 标准 中国
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1OKTAY K, SONMERZER M. Chemotherapy and amenorrhea: risks and treatment options [ J ] . Curr Opin Obstet Gynecol, 2008, 20(4): 408-415.
  • 2KIL W J, AHN S D, SHIN S S, et al. Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients [ J ] . Breast Cancer Res Treat, 2006, 96(3): 245- 250.
  • 3PETREK J A, NAUGHTON M J, CASE L D, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study [ J ] . J Clin Oncol, 2006, 24(7): 1045-1051.
  • 4李惠平,马力文,张淑兰,贾廷珍,邓惠静,张照辉,梁莉,王墨培,肖宇,曹保山,陈森,汪有蕃.绝经前乳腺癌化疗致闭经的观察及临床意义[J].中华肿瘤杂志,2006,28(11):848-851. 被引量：23
  • 5FORNIER M N, MODI S, PANAGEAS K S, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane [ J ] . Cancer, 2005, 104(8): 1575- 1579.
  • 6THAM Y L, SEXTON K, WEISS H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and eyelophosphamide followed by a taxane [ J ]. Am J Clin Oncol, 2007, 30(2): 126-132.
  • 7周力恒,殷文瑾,陆劲松,狄根红,吴炅,沈坤炜,韩企夏,沈镇宙,邵志敏.乳腺癌患者月经状态改变与化疗方案及年龄的关系[J].肿瘤,2007,27(12):999-1002. 被引量：8
  • 8SWAIN S M, LAND S R, SUNDRY J, et al. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C)---~docetaxel (1') arm of NSABP B-30: preliminary results [ J ] . Proc Am Soc Clin Oncol, 2005, 23(Suppl 16): 537.
  • 9COOMBES R C, KILBURN L S, SNOWDON C F, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trim [ J ] . Lancet, 2007, 369(9561): 559-570.
  • 10SMITH I E, DOWSE'IT M, YAP Y S, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines [ J ] . J Chn Oncol, 2006, 24(16): 2444--2447.

二级参考文献19

  • 1王佳玉,徐兵河.芳香化酶抑制剂在乳腺癌内分泌治疗中的地位及展望[J].中华肿瘤杂志,2004,26(8):507-508. 被引量：13
  • 2李惠平,马力文,张淑兰,贾廷珍,邓惠静,张照辉,梁莉,王墨培,肖宇,曹保山,陈森,汪有蕃.绝经前乳腺癌化疗致闭经的观察及临床意义[J].中华肿瘤杂志,2006,28(11):848-851. 被引量：23
  • 3Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA. 5. J Clin Oncol, 2005. 23:6002-6008
  • 4Di Cosimo S, Alimonti A, Ferretti G, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol, 2004,15 : 1065-1071.
  • 5Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. New Engl J Med, 2005, 352:2302-2313.
  • 6Del Mastro L, Venturini M, Sertoli MR, et al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat, 1997, 43:183-190.
  • 7Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol,1999, 17:2365-2370.
  • 8Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer.Cancer Control, 2002, 9:466-472.
  • 9JOMAT W, KAUFMANN M, SAUERBREI W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The zoladex early breast cancer research association study [J]. J Clin Oncol,2002 , 20(24) :4628-4635.
  • 10WINER E P, HUDIS C, BURSTEIN H J, et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 [ J]. J Clin Oncl, 2005, 23(3) :619-629.

共引文献27

同被引文献30

  • 1Smith I E, Dowsett M, Yap Y S, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy induced amenorrhoea caution and suggested guidelines [J]. J Clin 0ncol,2006,24(16)2444-2447.
  • 2Davies C, Pan H, Godwin J, etal. Long term effects of con tinuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381 (9869):805 816.
  • 3Hershman DL, KushiL H, ShaoT, etal. Early discontinua- tion and nonadherence to adiuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients[J]. J Clin Oncol,2010,28(27) :4120-4128.
  • 4Mortimer J E, Flatt SW, Parker B A, etal. Tamoxifen, hot flashes and recurrence in breast cancer[J]. Breast Cancer Res Treat, 2008,108(3) : :421-426.
  • 5Kelly C M, JuurlinkDN, Gomes T, etal. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study[J]. BMJ, 2010,340 : c693-c700.
  • 6Zafra-Ceres M, de Haro T, Farez Vidal E, etal. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabo- lites in Spanish women with breast cancer[J]. Int J Med Sci, 2013,10(7) :932-937.
  • 7Ruddy K .1, Desantis S D, Gelman R S, et aK Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice[J]. Breast Cancer Res Treat, 2013,141 (3) : 421 427.
  • 8周力恒,殷文瑾,陆劲松,狄根红,吴炅,沈坤炜,韩企夏,沈镇宙,邵志敏.乳腺癌患者月经状态改变与化疗方案及年龄的关系[J].肿瘤,2007,27(12):999-1002. 被引量：8
  • 9杨新明,吴绍洋,陈莉丽,钟科峰,章汝霜.三苯氧胺对乳腺癌围绝经期患者性激素水平的影响[J].中国医药导报,2011,8(30):74-75. 被引量：3
  • 10孙冰,孟祥颖,宋三泰,单彬,吴世凯,江泽飞,王涛,张少华.乳腺癌患者血清雌二醇、卵泡刺激素及黄体生成素检测结果分析:西门子吖啶酯化学发光法检测报告[J].中华乳腺病杂志（电子版）,2012,6(3):5-9. 被引量：6

引证文献7

二级引证文献10

中国癌症杂志
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部